{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.66","value":"-2.75"},{"groupId":"OG001","spread":"17.72","value":"-1.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.15","value":"-0.56"},{"groupId":"OG001","spread":"18.05","value":"-0.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"178"}],"units":"Participants"}],"title":"Cycle 3 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.16","value":"-0.05"},{"groupId":"OG001","spread":"19.37","value":"1.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"title":"Cycle 4 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.49","value":"0.65"},{"groupId":"OG001","spread":"20.67","value":"1.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Cycle 5 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.40","value":"0.06"},{"groupId":"OG001","spread":"19.52","value":"3.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"title":"Cycle 6 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.41","value":"-0.23"},{"groupId":"OG001","spread":"20.62","value":"3.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"title":"Cycle 7 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.65","value":"1.88"},{"groupId":"OG001","spread":"19.75","value":"0.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"title":"Cycle 8 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.03","value":"-0.19"},{"groupId":"OG001","spread":"20.32","value":"1.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Cycle 9 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.83","value":"0.21"},{"groupId":"OG001","spread":"20.61","value":"3.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"title":"Cycle 10 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.29","value":"-1.03"},{"groupId":"OG001","spread":"20.34","value":"1.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Cycle 11 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.91","value":"-0.31"},{"groupId":"OG001","spread":"21.08","value":"2.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"title":"Cycle 12 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.73","value":"0.89"},{"groupId":"OG001","spread":"18.57","value":"4.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Cycle 13 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.69","value":"0.25"},{"groupId":"OG001","spread":"21.35","value":"1.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"title":"Cycle 14 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.10","value":"-0.61"},{"groupId":"OG001","spread":"20.62","value":"0.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"Cycle 15 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.16","value":"1.18"},{"groupId":"OG001","spread":"21.13","value":"2.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"93"}],"units":"Participants"}],"title":"Cycle 16 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.97","value":"-0.32"},{"groupId":"OG001","spread":"20.46","value":"1.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"title":"Cycle 17 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.88","value":"-1.35"},{"groupId":"OG001","spread":"19.78","value":"0.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 18 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.05","value":"-1.88"},{"groupId":"OG001","spread":"22.24","value":"0.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"title":"Cycle 19 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.67","value":"-0.63"},{"groupId":"OG001","spread":"21.33","value":"-0.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Cycle 20 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.00","value":"0.33"},{"groupId":"OG001","spread":"21.17","value":"3.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Cycle 21 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.83","value":"3.99"},{"groupId":"OG001","spread":"20.21","value":"4.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"Cycle 22 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.19","value":"0.23"},{"groupId":"OG001","spread":"23.53","value":"6.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Cycle 23 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.27","value":"5.26"},{"groupId":"OG001","spread":"21.42","value":"8.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Cycle 24 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.00","value":"6.18"},{"groupId":"OG001","spread":"23.97","value":"6.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Cycle 25 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.38","value":"5.21"},{"groupId":"OG001","spread":"16.75","value":"4.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Cycle 26 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.18","value":"11.67"},{"groupId":"OG001","spread":"27.74","value":"16.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 27 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.39","value":"9.44"},{"groupId":"OG001","spread":"27.62","value":"9.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 28 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.48","value":"8.33"},{"groupId":"OG001","spread":"32.64","value":"14.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 29 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.95","value":"9.72"},{"groupId":"OG001","spread":"12.47","value":"5.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Cycle 30 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.42","value":"-5.62"},{"groupId":"OG001","spread":"21.64","value":"-3.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \\[5 items\\], role \\[2 items\\], emotional \\[4 items\\], cognitive \\[2 items\\], social \\[2 items\\]), symptom scales (fatigue \\[3 items\\], nausea \\& vomiting \\[2 items\\], pain \\[2 items\\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For GHS/QoL: overall health and quality of life were assessed, rated on a 7-point scale (1: very poor to 7: excellent). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for GHS/QoL and a positive change from baseline represents a healthy/better level of QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized population. Only those participants with data collected at specified timepoints are reported.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QoL)","type":"SECONDARY","unitOfMeasure":"score on a scale"}